101
|
Deweid L, Avrutina O, Kolmar H. Microbial transglutaminase for biotechnological and biomedical engineering. Biol Chem 2019; 400:257-274. [PMID: 30291779 DOI: 10.1515/hsz-2018-0335] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Accepted: 09/04/2018] [Indexed: 12/17/2022]
Abstract
Research on bacterial transglutaminase dates back to 1989, when the enzyme has been isolated from Streptomyces mobaraensis. Initially discovered during an extensive screening campaign to reduce costs in food manufacturing, it quickly appeared as a robust and versatile tool for biotechnological and pharmaceutical applications due to its excellent activity and simple handling. While pioneering attempts to make use of its extraordinary cross-linking ability resulted in heterogeneous polymers, currently it is applied to site-specifically ligate diverse biomolecules yielding precisely modified hybrid constructs comprising two or more components. This review covers the extensive and rapidly growing field of microbial transglutaminase-mediated bioconjugation with the focus on pharmaceutical research. In addition, engineering of the enzyme by directed evolution and rational design is highlighted. Moreover, cumbersome drawbacks of this technique mainly caused by the enzyme's substrate indiscrimination are discussed as well as the ways to bypass these limitations.
Collapse
Affiliation(s)
- Lukas Deweid
- Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Straße 4, D-64287 Darmstadt, Germany
| | - Olga Avrutina
- Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Straße 4, D-64287 Darmstadt, Germany
| | - Harald Kolmar
- Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Straße 4, D-64287 Darmstadt, Germany
| |
Collapse
|
102
|
Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol 2019; 12:94. [PMID: 31500657 PMCID: PMC6734251 DOI: 10.1186/s13045-019-0786-6] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Accepted: 08/29/2019] [Indexed: 12/13/2022] Open
Abstract
Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs therefore combine the immune therapy with targeted chemotherapy. Due to the distinct biomarkers associated with lymphocytes and plasma cells, ADCs have emerged as a promising treatment option for lymphoid malignancies and multiple myeloma. Several ADCs have been approved for clinical applications: brentuximab vedotin, inotuzumab ozogamicin, moxetumomab pasudotox, and polatuzumab vedotin. More novel ADCs are under clinical development. In this article, we summarized the general principles for ADC design, and updated novel ADCs under various stages of clinical trials for lymphoid malignancies and multiple myeloma.
Collapse
Affiliation(s)
- Bo Yu
- Department of Medicine, Lincoln Medical Center, Bronx, NY USA
| | - Delong Liu
- Department of Oncology, The First affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY USA
| |
Collapse
|
103
|
Walker JA, Bohn JJ, Ledesma F, Sorkin MR, Kabaria SR, Thornlow DN, Alabi CA. Substrate Design Enables Heterobifunctional, Dual “Click” Antibody Modification via Microbial Transglutaminase. Bioconjug Chem 2019; 30:2452-2457. [DOI: 10.1021/acs.bioconjchem.9b00522] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Joshua A. Walker
- Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, 113 Ho Plaza, Ithaca, New York 14850, United States
| | - John J. Bohn
- Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana−Champaign, 600 S Mathews Ave, Urbana, Illinois 61801, United States
| | - Francis Ledesma
- Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, 113 Ho Plaza, Ithaca, New York 14850, United States
| | - Michelle R. Sorkin
- Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, 113 Ho Plaza, Ithaca, New York 14850, United States
| | - Sneha R. Kabaria
- Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, 113 Ho Plaza, Ithaca, New York 14850, United States
| | - Dana N. Thornlow
- Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, 113 Ho Plaza, Ithaca, New York 14850, United States
| | - Christopher A. Alabi
- Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, 113 Ho Plaza, Ithaca, New York 14850, United States
| |
Collapse
|
104
|
Abstract
Cell-free systems (CFS) have recently evolved into key platforms for synthetic biology applications. Many synthetic biology tools have traditionally relied on cell-based systems, and while their adoption has shown great progress, the constraints inherent to the use of cellular hosts have limited their reach and scope. Cell-free systems, which can be thought of as programmable liquids, have removed many of these complexities and have brought about exciting opportunities for rational design and manipulation of biological systems. Here we review how these simple and accessible enzymatic systems are poised to accelerate the rate of advancement in synthetic biology and, more broadly, biotechnology.
Collapse
Affiliation(s)
- Aidan Tinafar
- Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St., Toronto, ON, M5S 3M2, Canada
| | - Katariina Jaenes
- Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St., Toronto, ON, M5S 3M2, Canada
| | - Keith Pardee
- Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St., Toronto, ON, M5S 3M2, Canada.
| |
Collapse
|
105
|
St. Amant AH, Huang F, Lin J, Lemen D, Chakiath C, Mao S, Fazenbaker C, Zhong H, Harper J, Xu W, Patel N, Adams L, Vijayakrishnan B, Howard PW, Marelli M, Wu H, Gao C, Read de Alaniz J, Christie RJ. A Reactive Antibody Platform for One-Step Production of Antibody–Drug Conjugates through a Diels–Alder Reaction with Maleimide. Bioconjug Chem 2019; 30:2340-2348. [DOI: 10.1021/acs.bioconjchem.9b00436] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Andre H. St. Amant
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106-9510, United States
| | - Fengying Huang
- Antibody Discovery and Protein Engineering Department, AstraZeneca R&D, Gaithersburg, Maryland 20878, United States
| | - Jia Lin
- Antibody Discovery and Protein Engineering Department, AstraZeneca R&D, Gaithersburg, Maryland 20878, United States
| | - Daniel Lemen
- Antibody Discovery and Protein Engineering Department, AstraZeneca R&D, Gaithersburg, Maryland 20878, United States
| | - Chacko Chakiath
- Antibody Discovery and Protein Engineering Department, AstraZeneca R&D, Gaithersburg, Maryland 20878, United States
| | - Shenlan Mao
- AstraZeneca Oncology R&D, Gaithersburg, Maryland 20878, United States
| | | | - Haihong Zhong
- AstraZeneca Oncology R&D, Gaithersburg, Maryland 20878, United States
| | - Jay Harper
- AstraZeneca Oncology R&D, Gaithersburg, Maryland 20878, United States
| | - Wenshu Xu
- Spirogen, London E1 2AX, United Kingdom
| | | | | | | | | | - Marcello Marelli
- AstraZeneca Oncology R&D, Gaithersburg, Maryland 20878, United States
| | - Herren Wu
- Antibody Discovery and Protein Engineering Department, AstraZeneca R&D, Gaithersburg, Maryland 20878, United States
| | - Changshou Gao
- Antibody Discovery and Protein Engineering Department, AstraZeneca R&D, Gaithersburg, Maryland 20878, United States
| | - Javier Read de Alaniz
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106-9510, United States
| | - R. James Christie
- Antibody Discovery and Protein Engineering Department, AstraZeneca R&D, Gaithersburg, Maryland 20878, United States
| |
Collapse
|
106
|
Bruins J, van de Wouw C, Wagner K, Bartels L, Albada B, van Delft FL. Highly Efficient Mono-Functionalization of Knob-in-Hole Antibodies with Strain-Promoted Click Chemistry. ACS OMEGA 2019; 4:11801-11807. [PMID: 31460288 PMCID: PMC6682001 DOI: 10.1021/acsomega.9b01727] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Accepted: 06/25/2019] [Indexed: 05/03/2023]
Abstract
Knob-in-hole antibodies can be utilized to introduce a single tag for chemo-enzymatic functionalization. By either introducing a single C-terminal sortase tag (sortase-tag expressed protein ligation) or tyrosine tag (G4Y), mono-functionalization of the monoclonal antibody trastuzumab was achieved rapidly and in high yields. This method was applied to selectively and efficiently introduce a single fluorescent tag, cytokine or single-chain variable fragment, as well as produce clean homo dimers of trastuzumab.
Collapse
Affiliation(s)
- Jorick
J. Bruins
- Laboratory
of Organic Chemistry, Wageningen University
& Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands
| | - Criss van de Wouw
- Laboratory
of Organic Chemistry, Wageningen University
& Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands
| | - Koen Wagner
- AIMM
Therapeutics, Meibergdreef
59, 1105 BA Amsterdam, The Netherlands
| | - Lina Bartels
- AIMM
Therapeutics, Meibergdreef
59, 1105 BA Amsterdam, The Netherlands
| | - Bauke Albada
- Laboratory
of Organic Chemistry, Wageningen University
& Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands
| | - Floris L. van Delft
- Laboratory
of Organic Chemistry, Wageningen University
& Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands
| |
Collapse
|
107
|
Yamada K, Ito Y. Recent Chemical Approaches for Site‐Specific Conjugation of Native Antibodies: Technologies toward Next‐Generation Antibody–Drug Conjugates. Chembiochem 2019; 20:2729-2737. [DOI: 10.1002/cbic.201900178] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Indexed: 11/09/2022]
Affiliation(s)
- Kei Yamada
- Ajinomoto Co., Inc. 1-1 Suzuki-Cho Kawasaki-Ku Kawasaki-Shi Kanagawa 210-8681 Japan
- Department of Chemistry and BioscienceGraduate School of Science and EngineeringKagoshima University 1-21-35 Korimoto Kagoshima 890-0065 Japan
| | - Yuji Ito
- Department of Chemistry and BioscienceGraduate School of Science and EngineeringKagoshima University 1-21-35 Korimoto Kagoshima 890-0065 Japan
| |
Collapse
|
108
|
Yang SO, Nielsen GH, Wilding KM, Cooper MA, Wood DW, Bundy BC. Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator. Methods Protoc 2019. [PMCID: PMC6632163 DOI: 10.3390/mps2020052] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Stroke is the leading cause of death with over 5 million deaths worldwide each year. About 80% of strokes are ischemic strokes caused by blood clots. Tissue plasminogen activator (tPa) is the only FDA-approved drug to treat ischemic stroke with a wholesale price over $6000. tPa is now off patent although no biosimilar has been developed. The production of tPa is complicated by the 17 disulfide bonds that exist in correctly folded tPA. Here, we present an Escherichia coli-based cell-free protein synthesis platform for tPa expression and report conditions which resulted in the production of active tPa. While the activity is below that of commercially available tPa, this work demonstrates the potential of cell-free expression systems toward the production of future biosimilars. The E. coli-based cell-free system is increasingly becoming an attractive platform for low-cost biosimilar production due to recent developments which enable production from shelf-stable lyophilized reagents, the removal of endotoxins from the reagents to prevent the risk of endotoxic shock, and rapid on-demand production in hours.
Collapse
Affiliation(s)
- Seung-Ook Yang
- Department of Chemical Engineering, Brigham Young University, Provo, UT 84602, USA; (S.-O.Y.); (G.H.N.); (K.M.W.)
| | - Gregory H. Nielsen
- Department of Chemical Engineering, Brigham Young University, Provo, UT 84602, USA; (S.-O.Y.); (G.H.N.); (K.M.W.)
| | - Kristen M. Wilding
- Department of Chemical Engineering, Brigham Young University, Provo, UT 84602, USA; (S.-O.Y.); (G.H.N.); (K.M.W.)
| | - Merideth A. Cooper
- Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH 43210, USA; (M.A.C.); (D.W.W.)
| | - David W. Wood
- Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH 43210, USA; (M.A.C.); (D.W.W.)
| | - Bradley C. Bundy
- Department of Chemical Engineering, Brigham Young University, Provo, UT 84602, USA; (S.-O.Y.); (G.H.N.); (K.M.W.)
- Correspondence:
| |
Collapse
|
109
|
Cao M, De Mel N, Jiao Y, Howard J, Parthemore C, Korman S, Thompson C, Wendeler M, Liu D. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis. MAbs 2019; 11:1064-1076. [PMID: 31198090 PMCID: PMC6748582 DOI: 10.1080/19420862.2019.1624127] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Site-specific antibody-drug conjugates (ADCs) are designed to overcome the heterogeneity observed with first-generation ADCs that use random conjugation to surface-exposed lysine residues or conjugation to interchain disulfide bonds. Despite significantly enhanced homogeneity, however, the production of site-specific ADCs yields some process-related species heterogeneity, including stereoisomers, unconjugated antibody, underconjugated species, and overconjugated species. An elevated level of size variants, such as heavy chain-light chain species (half ADC), heavy chain-heavy chain-light chain species, and light chain species, is also observed with the final site-specific ADC product. To understand the root cause of heterogeneity generated during the ADC conjugation process, we designed time-course studies for each conjugation step, including reduction, oxidation, conjugation, and quenching. We developed both non-reduced peptide map and LabChip-based capillary electrophoresis sodium dodecyl sulfate methods for time-course sample analysis. On the basis of our time-course data, the half ADC and unconjugated antibody were generated during oxidation as a result of alternative disulfide bond arrangements. During oxidation, two hinge cysteines formed an intra-chain disulfide bond in the half ADC, and three inter-chain hinge disulfide bonds were formed in the unconjugated antibody. Time-course data also showed that the elevated level of size variants, especially heavy chain-heavy chain-light chain species and light chain species, resulted from the quenching step, where the quenching reagent engaged in a disulfide bond exchange reaction with the ADC and broke the disulfide bonds connecting the heavy chain and light chain. Underconjugated and overconjugated species arose from the equilibrium established during the conjugation reaction.
Collapse
Affiliation(s)
- Mingyan Cao
- a Department of Analytical Sciences, MedImmune , Gaithersburg , MD , USA
| | - Niluka De Mel
- a Department of Analytical Sciences, MedImmune , Gaithersburg , MD , USA
| | - Yang Jiao
- a Department of Analytical Sciences, MedImmune , Gaithersburg , MD , USA
| | - James Howard
- b Department of Purification Process Sciences, MedImmune , Gaithersburg , MD , USA
| | - Conner Parthemore
- a Department of Analytical Sciences, MedImmune , Gaithersburg , MD , USA
| | - Samuel Korman
- a Department of Analytical Sciences, MedImmune , Gaithersburg , MD , USA
| | - Christopher Thompson
- b Department of Purification Process Sciences, MedImmune , Gaithersburg , MD , USA
| | - Michaela Wendeler
- b Department of Purification Process Sciences, MedImmune , Gaithersburg , MD , USA
| | - Dengfeng Liu
- a Department of Analytical Sciences, MedImmune , Gaithersburg , MD , USA
| |
Collapse
|
110
|
Maso K, Montagner IM, Grigoletto A, Schiavon O, Rosato A, Pasut G. A non-covalent antibody complex for the delivery of anti-cancer drugs. Eur J Pharm Biopharm 2019; 142:49-60. [PMID: 31201855 DOI: 10.1016/j.ejpb.2019.06.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 06/11/2019] [Accepted: 06/12/2019] [Indexed: 10/26/2022]
Abstract
Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important impact on their activity, characterization, and manufacturing. A new antibody drug delivery system (ADS) based on a non-covalent linkage between a Fc-binding protein, in this case Protein A or Protein G, and a mAb was investigated in the effort to achieve greater homogeneity and to create a versatile and adaptable drug delivery system. Recombinant staphylococcal Protein A and streptococcal Protein G were chemically PEGylated at the N-terminus with a 5 kDa and a 20 kDa PEG, respectively, yielding two monoconjugates with a mass of ≈50 and ≈45 kDa. Circular dichroism studies showed that both conjugates preserved secondary structures of the protein, and isothermal titration calorimetry experiments demonstrated that their affinity for mAb was approximately 107 M-1. Upon complexation with a mAb (Trastuzumab or Rituximab), in vitro flow-cytometry analysis of the new ADSs showed high selectivity for the specific antigen expressing cells. In addition, the ADS complex based on Trastuzumab and Protein G, conjugated with a heterobifunctional 20 kDa PEG carrying the toxin Tubulysin A, had a marked cytotoxic effect on the cancer cell line overexpressing the HER2/neu receptor, thus supporting its application in cancer therapy.
Collapse
Affiliation(s)
- Katia Maso
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | | | - Antonella Grigoletto
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Oddone Schiavon
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Antonio Rosato
- Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Gattamelata 64, 35128 Padova, Italy.
| | - Gianfranco Pasut
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy; Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
| |
Collapse
|
111
|
Gao W, Cho E, Liu Y, Lu Y. Advances and Challenges in Cell-Free Incorporation of Unnatural Amino Acids Into Proteins. Front Pharmacol 2019; 10:611. [PMID: 31191324 PMCID: PMC6549004 DOI: 10.3389/fphar.2019.00611] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Accepted: 05/15/2019] [Indexed: 12/17/2022] Open
Abstract
Incorporation of unnatural amino acids (UNAAs) into proteins currently is an active biological research area for various fundamental and applied science. In this context, cell-free synthetic biology (CFSB) has been developed and recognized as a robust testing and biomanufacturing platform for highly efficient UNAA incorporation. It enables the orchestration of unnatural biological machinery toward an exclusive user-defined objective of unnatural protein synthesis. This review aims to overview the principles of cell-free unnatural protein synthesis (CFUPS) systems, their advantages, different UNAA incorporation approaches, and recent achievements. These have catalyzed cutting-edge research and diverse emerging applications. Especially, present challenges and future trends are focused and discussed. With the development of CFSB and the fusion with other advanced next-generation technologies, CFUPS systems would explicitly deliver their values for biopharmaceutical applications.
Collapse
Affiliation(s)
- Wei Gao
- Department of Chemical Engineering, Tsinghua University, Beijing, China
- College of Life Science, Shenyang Normal University, Shenyang, China
| | - Eunhee Cho
- Department of Chemical Engineering, Tsinghua University, Beijing, China
| | - Yingying Liu
- Department of Chemical Engineering, Tsinghua University, Beijing, China
- College of Life Science, Shenyang Normal University, Shenyang, China
| | - Yuan Lu
- Department of Chemical Engineering, Tsinghua University, Beijing, China
- Institute of Biochemical Engineering, Department of Chemical Engineering, Tsinghua University, Beijing, China
- Key Lab of Industrial Biocatalysis, Ministry of Education, Department of Chemical Engineering, Tsinghua University, Beijing, China
| |
Collapse
|
112
|
Thornlow DN, Cox EC, Walker JA, Sorkin M, Plesset JB, DeLisa MP, Alabi CA. Dual Site-Specific Antibody Conjugates for Sequential and Orthogonal Cargo Release. Bioconjug Chem 2019; 30:1702-1710. [PMID: 31083974 DOI: 10.1021/acs.bioconjchem.9b00244] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Antibody-drug conjugates utilize the antigen specificity of antibodies and the potency of chemotherapeutic and antibiotic drugs for targeted therapy. However, as cancers and bacteria evolve to resist the action of drugs, innovative controlled release methods must be engineered to deliver multidrug cocktails. In this work, we engineer lipoate-acid ligase A (LplA) acceptor peptide (LAP) tags into the constant heavy and light chain of a humanized Her2 targeted antibody, trastuzumab. These engineered LAP tags, along with the glutamine 295 (Q295) residue in the heavy chain, were used to generate orthogonally cleavable site-specific antibody conjugates via a one-pot chemoenzymatic ligation with microbial transglutaminase (mTG) and LplA. We demonstrate orthogonal cargo release from these dual-labeled antibody bioconjugates via matrix metalloproteinase-2 and cathepsin-B-mediated bond cleavage. To the best of our knowledge, this is the first demonstration of temporal control on dual-labeled antibody conjugates, and we believe this platform will allow for sequential release and cooperative drug combinations on a single antibody bioconjugate.
Collapse
Affiliation(s)
- Dana N Thornlow
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| | - Emily C Cox
- Biological and Biomedical Sciences , Cornell University College of Veterinary Medicine , Ithaca , New York 14853 , United States
| | - Joshua A Walker
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| | - Michelle Sorkin
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| | - Jacqueline B Plesset
- Meinig School of Biomedical Engineering , Cornell University , Ithaca , New York 14853 , United States
| | - Matthew P DeLisa
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| | - Christopher A Alabi
- Robert F. Smith School of Chemical and Biomolecular Engineering , Cornell University , 120 Olin Hall, Ithaca , New York 14853 , United States
| |
Collapse
|
113
|
Saleh AM, Wilding KM, Calve S, Bundy BC, Kinzer-Ursem TL. Non-canonical amino acid labeling in proteomics and biotechnology. J Biol Eng 2019; 13:43. [PMID: 31139251 PMCID: PMC6529998 DOI: 10.1186/s13036-019-0166-3] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Accepted: 04/11/2019] [Indexed: 02/03/2023] Open
Abstract
Metabolic labeling of proteins with non-canonical amino acids (ncAAs) provides unique bioorthogonal chemical groups during de novo synthesis by taking advantage of both endogenous and heterologous protein synthesis machineries. Labeled proteins can then be selectively conjugated to fluorophores, affinity reagents, peptides, polymers, nanoparticles or surfaces for a wide variety of downstream applications in proteomics and biotechnology. In this review, we focus on techniques in which proteins are residue- and site-specifically labeled with ncAAs containing bioorthogonal handles. These ncAA-labeled proteins are: readily enriched from cells and tissues for identification via mass spectrometry-based proteomic analysis; selectively purified for downstream biotechnology applications; or labeled with fluorophores for in situ analysis. To facilitate the wider use of these techniques, we provide decision trees to help guide the design of future experiments. It is expected that the use of ncAA labeling will continue to expand into new application areas where spatial and temporal analysis of proteome dynamics and engineering new chemistries and new function into proteins are desired.
Collapse
Affiliation(s)
- Aya M. Saleh
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN USA
| | - Kristen M. Wilding
- Department of Chemical Engineering, Brigham Young University, Provo, UT USA
| | - Sarah Calve
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN USA
| | - Bradley C. Bundy
- Department of Chemical Engineering, Brigham Young University, Provo, UT USA
| | | |
Collapse
|
114
|
Chu C, Su M, Zhu J, Li D, Cheng H, Chen X, Liu G. Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment. Theranostics 2019; 9:3134-3149. [PMID: 31244946 PMCID: PMC6567975 DOI: 10.7150/thno.33539] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2019] [Accepted: 03/20/2019] [Indexed: 02/05/2023] Open
Abstract
Cancer treatment using functional proteins, DNA/RNA, or complex bio-entities is important in both preclinical and clinical studies. With the help of nano-delivery systems, these biomacromolecules can enrich cancer tissues to match the clinical requirements. Biomineralization via a self-assembly process has been widely applied to provide biomacromolecules exoskeletal-like protection for immune shielding and preservation of bioactivity. Advanced metal-organic framework nanoparticles (MOFs) are excellent supporting matrices due to the low toxicity of polycarboxylic acids and metals, high encapsulation efficiency, and moderate synthetic conditions. In this review, we study MOFs-based biomineralization for cancer treatment and summarize the unique properties of MOF hybrids. We also evaluate the outlook of potential cancer treatment applications for MOFs-based biomineralization. This strategy likely opens new research orientations for cancer theranostics.
Collapse
Affiliation(s)
- Chengchao Chu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health Xiamen, Xiamen University, Xiamen 361102, China
| | - Min Su
- State Key Laboratory of Physical Chemistry of Solid Surfaces & The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China
| | - Jing Zhu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health Xiamen, Xiamen University, Xiamen 361102, China
| | - Dongsheng Li
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health Xiamen, Xiamen University, Xiamen 361102, China
| | - Hongwei Cheng
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health Xiamen, Xiamen University, Xiamen 361102, China
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892, USA
| | - Gang Liu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health Xiamen, Xiamen University, Xiamen 361102, China
- State Key Laboratory of Physical Chemistry of Solid Surfaces & The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China
| |
Collapse
|
115
|
St Amant AH, Huang F, Lin J, Rickert K, Oganesyan V, Lemen D, Mao S, Harper J, Marelli M, Wu H, Gao C, Read de Alaniz J, Christie RJ. A Diene-Containing Noncanonical Amino Acid Enables Dual Functionality in Proteins: Rapid Diels-Alder Reaction with Maleimide or Proximity-Based Dimerization. Angew Chem Int Ed Engl 2019; 58:8489-8493. [PMID: 31018033 DOI: 10.1002/anie.201903494] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Indexed: 12/19/2022]
Abstract
Here, we describe a diene-containing noncanonical amino acid (ncAA) capable of undergoing fast and selective normal electron-demand Diels-Alder (DA) reactions following its incorporation into antibodies. A cyclopentadiene derivative of lysine (CpHK) served as the reactive handle for DA transformations and the substrate for genetic incorporation. CpHK incorporated into antibodies with high efficiency and was available for maleimide conjugation or self-reaction depending on position in the amino acid sequence. CpHK at position K274 reacted with the maleimide drug-linker AZ1508 at a rate of ≈79 m-1 s-1 to produce functional antibody-drug conjugates (ADCs) in a one-step process. Incorporation of CpHK at position S239 resulted in dimerization, which covalently linked antibody heavy chains together. The diene ncAA described here is capable of producing therapeutic protein conjugates with clinically validated and widely available maleimide compounds, while also enabling proximity-based stapling through a DA dimerization reaction.
Collapse
Affiliation(s)
- Andre H St Amant
- Department of Chemistry and Biochemistry, University of California - Santa Barbara, Santa Barbara, California, 93106, USA
| | - Fengying Huang
- Antibody Discovery and Protein Engineering Department, AstraZeneca Biopharmaceuticals R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Jia Lin
- Antibody Discovery and Protein Engineering Department, AstraZeneca Biopharmaceuticals R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Keith Rickert
- Antibody Discovery and Protein Engineering Department, AstraZeneca Biopharmaceuticals R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Vaheh Oganesyan
- Antibody Discovery and Protein Engineering Department, AstraZeneca Biopharmaceuticals R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Daniel Lemen
- Antibody Discovery and Protein Engineering Department, AstraZeneca Biopharmaceuticals R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Shenlan Mao
- AstraZeneca Oncology R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Jay Harper
- AstraZeneca Oncology R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Marcello Marelli
- Antibody Discovery and Protein Engineering Department, AstraZeneca Biopharmaceuticals R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Herren Wu
- Antibody Discovery and Protein Engineering Department, AstraZeneca Biopharmaceuticals R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Changshou Gao
- Antibody Discovery and Protein Engineering Department, AstraZeneca Biopharmaceuticals R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| | - Javier Read de Alaniz
- Department of Chemistry and Biochemistry, University of California - Santa Barbara, Santa Barbara, California, 93106, USA
| | - R James Christie
- Antibody Discovery and Protein Engineering Department, AstraZeneca Biopharmaceuticals R&D, One MedImmune Way, Gaithersburg, MD, 20878, USA
| |
Collapse
|
116
|
St. Amant AH, Huang F, Lin J, Rickert K, Oganesyan V, Lemen D, Mao S, Harper J, Marelli M, Wu H, Gao C, Read de Alaniz J, Christie RJ. A Diene‐Containing Noncanonical Amino Acid Enables Dual Functionality in Proteins: Rapid Diels–Alder Reaction with Maleimide or Proximity‐Based Dimerization. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201903494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Andre H. St. Amant
- Department of Chemistry and BiochemistryUniversity of California – Santa Barbara Santa Barbara California 93106 USA
| | - Fengying Huang
- Antibody Discovery and Protein Engineering DepartmentAstraZeneca Biopharmaceuticals R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Jia Lin
- Antibody Discovery and Protein Engineering DepartmentAstraZeneca Biopharmaceuticals R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Keith Rickert
- Antibody Discovery and Protein Engineering DepartmentAstraZeneca Biopharmaceuticals R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Vaheh Oganesyan
- Antibody Discovery and Protein Engineering DepartmentAstraZeneca Biopharmaceuticals R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Daniel Lemen
- Antibody Discovery and Protein Engineering DepartmentAstraZeneca Biopharmaceuticals R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Shenlan Mao
- AstraZeneca Oncology R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Jay Harper
- AstraZeneca Oncology R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Marcello Marelli
- Antibody Discovery and Protein Engineering DepartmentAstraZeneca Biopharmaceuticals R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Herren Wu
- Antibody Discovery and Protein Engineering DepartmentAstraZeneca Biopharmaceuticals R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Changshou Gao
- Antibody Discovery and Protein Engineering DepartmentAstraZeneca Biopharmaceuticals R&D One MedImmune Way Gaithersburg MD 20878 USA
| | - Javier Read de Alaniz
- Department of Chemistry and BiochemistryUniversity of California – Santa Barbara Santa Barbara California 93106 USA
| | - R. James Christie
- Antibody Discovery and Protein Engineering DepartmentAstraZeneca Biopharmaceuticals R&D One MedImmune Way Gaithersburg MD 20878 USA
| |
Collapse
|
117
|
Garcia A, Roy G, Kiefer C, Wilson S, Marelli M. qPCR assays to quantitate tRNApyl and pylRS expression in engineered cell lines. PLoS One 2019; 14:e0216356. [PMID: 31071154 PMCID: PMC6508675 DOI: 10.1371/journal.pone.0216356] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 04/18/2019] [Indexed: 11/18/2022] Open
Abstract
Non-natural amino acids (nnAA) contain unique functional moieties that greatly expand the available tool set for protein engineering. But incorporation of nnAAs requires the function of an orthogonal aminoacyl tRNA synthetase/tRNA pair. Stable cell lines expressing these components have been shown capable of producing gram per liter levels of antibodies with nnAAs. However, little has been reported on the genetic makeup of these cells. To gain a better understanding of the minimal requirements for efficient nnAA incorporation we developed qPCR methods for the quantitation of the key components. Here we describe the development of qPCR assays for the quantification of tRNApyl and pylRS. qPCR was chosen because it provides a large dynamic range, has high specificity for its target, and is a non-radioactive method used routinely for cell line characterization. Designing assays for tRNAs present challenges due to their short length (~72 nucleotides) and high secondary structure. These tRNA assays have a ≥ 5 log dynamic range with the tRNApyl assays being able to discern the mature and unprocessed forms of the tRNApyl. Cell line analysis showed tRNApyl was expressed at higher levels than the CHO-K1 endogenous Met and Phe tRNAs and that >88% of tRNApyl was the mature form.
Collapse
Affiliation(s)
- Andrew Garcia
- Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, MD, United States of America
| | - Gargi Roy
- Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, MD, United States of America
| | - Christine Kiefer
- Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, MD, United States of America
| | - Susan Wilson
- Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, MD, United States of America
| | - Marcello Marelli
- Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, MD, United States of America
- * E-mail:
| |
Collapse
|
118
|
Manabe S, Yamaguchi Y, Matsumoto K, Fuchigami H, Kawase T, Hirose K, Mitani A, Sumiyoshi W, Kinoshita T, Abe J, Yasunaga M, Matsumura Y, Ito Y. Characterization of Antibody Products Obtained through Enzymatic and Nonenzymatic Glycosylation Reactions with a Glycan Oxazoline and Preparation of a Homogeneous Antibody-Drug Conjugate via Fc N-Glycan. Bioconjug Chem 2019; 30:1343-1355. [PMID: 30938513 DOI: 10.1021/acs.bioconjchem.9b00132] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Glycan engineering of antibodies has received considerable attention. Although various endo-β- N-acetylglucosaminidase mutants have been developed for glycan remodeling, a side reaction has been reported between glycan oxazoline and amino groups. In this study, we performed a detailed characterization for antibody products obtained through enzymatic and nonenzymatic reactions with the aim of maximizing the efficiency of the glycosylation reaction with fewer side products. The reactions were monitored by an ultraperformance liquid chromatography system using an amide-based wide-pore column. The products were characterized by liquid chromatography coupled with tandem mass spectrometry. The side reactions were suppressed by adding glycan oxazoline in a stepwise manner under slightly acidic conditions. Through a combination of an azide-carrying glycan transfer reaction under optimized conditions and a bio-orthogonal reaction, a potent cytotoxic agent monomethyl auristatin E was site-specifically conjugated at N-glycosylated Asn297 with a drug-to-antibody ratio of 4. The prepared antibody-drug conjugate exhibited cytotoxicity against HER2-expressing cells.
Collapse
Affiliation(s)
- Shino Manabe
- Synthetic Cellular Chemistry Laboratory , RIKEN , Hirosawa, Wako , Saitama , 351-0198 Japan
| | - Yoshiki Yamaguchi
- Synthetic Cellular Chemistry Laboratory , RIKEN , Hirosawa, Wako , Saitama , 351-0198 Japan.,Structural Glycobiology Team , RIKEN , Hirosawa, Wako , Saitama , 351-0198 Japan
| | - Kana Matsumoto
- Structural Glycobiology Team , RIKEN , Hirosawa, Wako , Saitama , 351-0198 Japan
| | - Hirobumi Fuchigami
- Exploratory Oncology Research & Clinical Trial Center , National Cancer Center , Kashiwanoha, Kashiwa , Chiba 277-8577 Japan
| | - Taiji Kawase
- Nihon Waters KK, Kitashinagawa, Shinagawa, Tokyo , 140-0001 Japan
| | - Kenji Hirose
- Nihon Waters KK, Kitashinagawa, Shinagawa, Tokyo , 140-0001 Japan
| | - Ai Mitani
- Fushimi Pharmaceutical Co. Ltd., Nakatsu, Marugame , Kagawa , 763-8605 Japan
| | - Wataru Sumiyoshi
- Fushimi Pharmaceutical Co. Ltd., Nakatsu, Marugame , Kagawa , 763-8605 Japan
| | - Takashi Kinoshita
- Fushimi Pharmaceutical Co. Ltd., Nakatsu, Marugame , Kagawa , 763-8605 Japan
| | - Junpei Abe
- Synthetic Cellular Chemistry Laboratory , RIKEN , Hirosawa, Wako , Saitama , 351-0198 Japan
| | - Masahiro Yasunaga
- Exploratory Oncology Research & Clinical Trial Center , National Cancer Center , Kashiwanoha, Kashiwa , Chiba 277-8577 Japan
| | - Yasuhiro Matsumura
- Exploratory Oncology Research & Clinical Trial Center , National Cancer Center , Kashiwanoha, Kashiwa , Chiba 277-8577 Japan
| | - Yukishige Ito
- Synthetic Cellular Chemistry Laboratory , RIKEN , Hirosawa, Wako , Saitama , 351-0198 Japan
| |
Collapse
|
119
|
Arlotta KJ, Owen SC. Antibody and antibody derivatives as cancer therapeutics. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2019; 11:e1556. [DOI: 10.1002/wnan.1556] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Revised: 02/20/2019] [Accepted: 03/10/2019] [Indexed: 12/20/2022]
Affiliation(s)
- Keith J. Arlotta
- Department of Biomedical Engineering University of Utah Salt Lake City Utah
| | - Shawn C. Owen
- Department of Biomedical Engineering University of Utah Salt Lake City Utah
- Department of Pharmaceutics and Pharmaceutical Chemistry University of Utah Salt Lake City Utah
| |
Collapse
|
120
|
Tobola F, Sylvander E, Gafko C, Wiltschi B. 'Clickable lectins': bioorthogonal reactive handles facilitate the directed conjugation of lectins in a modular fashion. Interface Focus 2019; 9:20180072. [PMID: 30842873 DOI: 10.1098/rsfs.2018.0072] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2018] [Indexed: 01/07/2023] Open
Abstract
Lectins are carbohydrate-binding proteins with specificity for their target ligands. They play diverse roles in cellular recognition and signalling processes, as well as in infections and cancer metastasis. Owing to their specificity, lectins find application in biotechnology and medicine, e.g. for blood group typing, purification of glycoproteins or lipids and as markers that target cancer cells. For some applications, lectins are immobilized on a solid support, or they are conjugated with other molecules. Classical protein conjugation reactions at nucleophilic amino acids such as cysteine or lysine are often non-selective, and the site of conjugation is difficult to pre-define. Random conjugation, however, can interfere with protein function. Therefore, we sought to equip lectins with a unique reactive handle, which can be conjugated with other molecules in a pre-defined manner. We site-specifically introduced non-canonical amino acids carrying bioorthogonal reactive groups into several lectins. As a proof of principle, we conjugated these 'clickable lectins' with small molecules. Furthermore, we conjugated lectins with different ligand specificities with one another to produce superlectins. The 'clickable lectins' might be useful for any process where lectins shall be conjugated with another module in a selective, pre-defined and site-specific manner.
Collapse
Affiliation(s)
- Felix Tobola
- Austrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria.,Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria
| | - Elise Sylvander
- Austrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria
| | - Claudia Gafko
- Austrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria.,Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria
| | - Birgit Wiltschi
- Austrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria
| |
Collapse
|
121
|
Li DZ, Han BN, Wei R, Yao GY, Chen Z, Liu J, Poon TCW, Su W, Zhu Z, Dimitrov DS, Zhao Q. N-terminal α-amino group modification of antibodies using a site-selective click chemistry method. MAbs 2019; 10:712-719. [PMID: 29652547 DOI: 10.1080/19420862.2018.1463122] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
Site-specific conjugation of small molecules to antibody molecules is a promising strategy for generation of antibody-drug conjugates. In this report, we describe the successful synthesis of a novel bifunctional molecule, 6-(azidomethyl)-2-pyridinecarboxyaldehyde (6-AM-2-PCA), which was used for conjugation of small molecules to peptides and antibodies. We demonstrated that 6-AM-2-PCA selectively reacted with N-terminal amino groups of peptides and antibodies. In addition, the azide group of 6-AM-2-PCA enabled copper-free click chemistry coupling with dibenzocyclooctyne-containing reagents. Bifunctional 6-AM-2-PCA mediated site-specific conjugation without requiring genetic engineering of peptides or antibodies. A key advantage of 6-AM-2-PCA as a conjugation reagent is its ability to modify proteins in a single step under physiological conditions that are sufficiently moderate to retain protein function. Therefore, this new click chemistry-based method could be a useful complement to other conjugation methods.
Collapse
Affiliation(s)
- De-Zhi Li
- a Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center , Guangdong , China
| | - Bing-Nan Han
- b Department of Development Technology of Marine Resources , School of Life Science, Zhejiang Sci-Tech University , Zhejiang , China
| | - Rui Wei
- c Faculty of Health Sciences, University of Macau , Macau , China
| | - Gui-Yang Yao
- d Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences , Guangdong , China
| | - Zhizhen Chen
- c Faculty of Health Sciences, University of Macau , Macau , China
| | - Jie Liu
- c Faculty of Health Sciences, University of Macau , Macau , China
| | - Terence C W Poon
- c Faculty of Health Sciences, University of Macau , Macau , China
| | - Wu Su
- d Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences , Guangdong , China
| | - Zhongyu Zhu
- e Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, NIH , USA
| | - Dimiter S Dimitrov
- f Department of Medicine, Center for Antibody Therapeutics , University of Pittsburgh Medical School , Pennsylvania , USA
| | - Qi Zhao
- c Faculty of Health Sciences, University of Macau , Macau , China
| |
Collapse
|
122
|
Gregorio NE, Levine MZ, Oza JP. A User's Guide to Cell-Free Protein Synthesis. Methods Protoc 2019; 2:E24. [PMID: 31164605 PMCID: PMC6481089 DOI: 10.3390/mps2010024] [Citation(s) in RCA: 126] [Impact Index Per Article: 25.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 03/05/2019] [Accepted: 03/06/2019] [Indexed: 02/06/2023] Open
Abstract
Cell-free protein synthesis (CFPS) is a platform technology that provides new opportunities for protein expression, metabolic engineering, therapeutic development, education, and more. The advantages of CFPS over in vivo protein expression include its open system, the elimination of reliance on living cells, and the ability to focus all system energy on production of the protein of interest. Over the last 60 years, the CFPS platform has grown and diversified greatly, and it continues to evolve today. Both new applications and new types of extracts based on a variety of organisms are current areas of development. However, new users interested in CFPS may find it challenging to implement a cell-free platform in their laboratory due to the technical and functional considerations involved in choosing and executing a platform that best suits their needs. Here we hope to reduce this barrier to implementing CFPS by clarifying the similarities and differences amongst cell-free platforms, highlighting the various applications that have been accomplished in each of them, and detailing the main methodological and instrumental requirement for their preparation. Additionally, this review will help to contextualize the landscape of work that has been done using CFPS and showcase the diversity of applications that it enables.
Collapse
Affiliation(s)
- Nicole E Gregorio
- Center for Applications in Biotechnology, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
- Department of Chemistry and Biochemistry, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
| | - Max Z Levine
- Center for Applications in Biotechnology, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
- Department of Biological Sciences, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
| | - Javin P Oza
- Center for Applications in Biotechnology, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
- Department of Chemistry and Biochemistry, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
| |
Collapse
|
123
|
Gerrits M, Budisa N, Merk H. Site-Specific Chemoselective Pyrrolysine Analogues Incorporation Using the Cell-Free Protein Synthesis System. ACS Synth Biol 2019; 8:381-390. [PMID: 30589532 DOI: 10.1021/acssynbio.8b00421] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Cell-free protein synthesis (CFPS) is a fast and convenient way to synthesize proteins for analytical studies and applications. CFPS, when equipped with a suitable orthogonal pair, allows for protein-site-directed labeling with desired functionalities such as fluorescent dyes or therapeutic groups that are needed to tailor proteins for analytical applications. In this context, chemoselective reactive pyrrolysine analogues (CR-OAs) are of particular value, as this class of unnatural amino acids, among other useful properties, covers a wide range of different chemoselective reactions. In this study, we present a flexible approach that facilitates incorporation of CR-OAs in CFPS systems. In particular, a fairly simple addition of two expression plasmids in our cell-free system, one encoding pyrrolysyl-tRNA synthetase and the other one the target protein, enabled ribosomal synthesis of proteins in the half-milligram range with the pre-installed orthogonal reactivity, easily modifiable by using mild, copper-free bioorthogonal chemistry. Our CFPS system allows rapid and highly customizable expression, as shown by several examples of successful site-directed fluorescence labeling. The feasibility of our CFPS system for protein analytics is further proved by demonstrating the functional integrity of a labeled protein by interaction measurements using microscale thermophoresis.
Collapse
Affiliation(s)
- Michael Gerrits
- Biocatalysis Group, Department of Chemistry, Technische Universität Berlin, 10623 Berlin, Germany
- biotechrabbit GmbH, 12489 Berlin, Germany
| | - Nediljko Budisa
- Biocatalysis Group, Department of Chemistry, Technische Universität Berlin, 10623 Berlin, Germany
- Chemical Synthetic Biology, Department of Chemistry, University of Manitoba, 144 Dysart Road, R3T 2N2 Winnipeg, MB, Canada
| | | |
Collapse
|
124
|
Huang N, Shimomura E, Yin G, Tran C, Sato A, Steiner A, Heibeck T, Tam M, Fairman J, Gibson FC. Immunization with cell-free-generated vaccine protects from Porphyromonas gingivalis-induced alveolar bone loss. J Clin Periodontol 2019; 46:197-205. [PMID: 30578564 PMCID: PMC7891626 DOI: 10.1111/jcpe.13047] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Revised: 12/11/2018] [Accepted: 12/15/2018] [Indexed: 12/19/2022]
Abstract
Introduction Periodontal diseases (PD) are complex oral inflammatory diseases initiated by keystone bacteria such as Porphyromonas gingivalis. A vaccine for PD is desirable as clinical treatment involves protracted maintenance strategies aimed to retain dentition. Although prior immunization approaches targeting P. gingivalis have reported variable success in limiting facets of disease such as oral bone loss, it remains that a vaccine for this disease may be attainable. Aim To investigate cell‐free protein synthesis (CFPS) as a platform to produce vaccinable targets suitable for efficacy testing in a P. gingivalis‐induced murine oral bone loss model. Materials and Methods Recombinantly generated P. gingivalis minor fimbriae protein (Mfa1), RgpA gingipain hemagglutinin domain 1 (HA1), and RgpA gingipain hemagglutinin domain 2 (HA2) were combined in equivalent doses in adjuvants and injected intramuscularly to immunize mice. Serum levels of protein‐specific antibody were measured by ELISA, and oral bone levels were defined by morphometrics. Results Recombinantly generated P. gingivalis proteins possessed high fidelity to predicted size and elicited protein‐specific IgG following immunization. Importantly, immunization with the vaccine cocktail protected from P. gingivalis elicited oral bone loss. Conclusion These data verify the utility of the CFPS technology to synthesize proteins that have the capacity to serve as novel vaccines.
Collapse
Affiliation(s)
- Nasi Huang
- Department of Medicine, Section of Infectious Diseases, School of Medicine, Boston University, Boston, Massachusetts
| | | | - Gang Yin
- Sutro BioPharma, South San Francisco, California
| | - Cuong Tran
- Sutro BioPharma, South San Francisco, California
| | - Aaron Sato
- Sutro BioPharma, South San Francisco, California
| | - Alex Steiner
- Sutro BioPharma, South San Francisco, California
| | | | - Michelle Tam
- Sutro BioPharma, South San Francisco, California
| | | | - Frank C Gibson
- Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, Florida
| |
Collapse
|
125
|
Walsh SJ, Omarjee S, Galloway WRJD, Kwan TTL, Sore HF, Parker JS, Hyvönen M, Carroll JS, Spring DR. A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates. Chem Sci 2019; 10:694-700. [PMID: 30774870 PMCID: PMC6349026 DOI: 10.1039/c8sc04645j] [Citation(s) in RCA: 84] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 11/06/2018] [Indexed: 12/11/2022] Open
Abstract
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilize the specificity of antibodies to selectively deliver highly potent cytotoxins to target cells. Although recent years have witnessed significant interest in ADCs, problems remain with the standard linkage chemistries used for cytotoxin-antibody bioconjugation. These typically (1) generate unstable constructs, which may lead to premature cytotoxin release, (2) often give a wide variance in drug-antibody ratios (DAR) and (3) have poor control of attachment location on the antibody, resulting in a variable pharmacokinetic profile. Herein, we report a novel divinylpyrimidine (DVP) linker platform for selective bioconjugation via covalent re-bridging of reduced disulfide bonds on native antibodies. Model studies using the non-engineered trastuzumab antibody validate the utility of this linker platform for the generic generation of highly plasma-stable and functional antibody constructs that incorporate variable biologically relevant payloads (including cytotoxins) in an efficient and site-selective manner with precise control over DAR. DVP linkers were also used to efficiently re-bridge both monomeric and dimeric protein systems, demonstrating their potential utility for general protein modification, protein stabilisation or the development of other protein-conjugate therapeutics.
Collapse
Affiliation(s)
- Stephen J Walsh
- Department of Chemistry , University of Cambridge , Cambridge , CB2 1EW , UK .
| | - Soleilmane Omarjee
- Cancer Research UK Cambridge Institute , University of Cambridge , Cambridge , CB2 0RE , UK .
| | | | - Terence T-L Kwan
- Department of Chemistry , University of Cambridge , Cambridge , CB2 1EW , UK .
| | - Hannah F Sore
- Department of Chemistry , University of Cambridge , Cambridge , CB2 1EW , UK .
| | - Jeremy S Parker
- Early Chemical Development , Pharmaceutical Development , IMED Biotech Unit , AstraZeneca , Macclesfield , UK
| | - Marko Hyvönen
- Department of Biochemistry , University of Cambridge , Cambridge , CB2 1GA , UK
| | - Jason S Carroll
- Cancer Research UK Cambridge Institute , University of Cambridge , Cambridge , CB2 0RE , UK .
| | - David R Spring
- Department of Chemistry , University of Cambridge , Cambridge , CB2 1EW , UK .
| |
Collapse
|
126
|
Kishimoto S, Nakashimada Y, Yokota R, Hatanaka T, Adachi M, Ito Y. Site-Specific Chemical Conjugation of Antibodies by Using Affinity Peptide for the Development of Therapeutic Antibody Format. Bioconjug Chem 2019; 30:698-702. [DOI: 10.1021/acs.bioconjchem.8b00865] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Satoshi Kishimoto
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima 890-0065, Japan
| | - Yuichi Nakashimada
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima 890-0065, Japan
| | - Riri Yokota
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima 890-0065, Japan
| | - Takaaki Hatanaka
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima 890-0065, Japan
| | - Motoyasu Adachi
- Tokai Quantum Beam Science Center, National Institutes for Quantum and Radiological Science and Technology, 2-4 Shirakata, Tokai, Ibaraki 319-1106, Japan
| | - Yuji Ito
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima 890-0065, Japan
| |
Collapse
|
127
|
Whedon SD, Parker MK, Tyson EL, Ritterhoff T, Shelton PMM, Chatterjee C. A clickable glutamine (CliQ) derivative for the traceless reversible modification of peptides and proteins. Chem Commun (Camb) 2019; 55:2043-2045. [DOI: 10.1039/c8cc09404g] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The Cu(i)-mediated click reaction of proteins with affinity tags enables their selective isolation from complex mixtures.
Collapse
|
128
|
Liu WQ, Zhang L, Chen M, Li J. Cell-free protein synthesis: Recent advances in bacterial extract sources and expanded applications. Biochem Eng J 2019. [DOI: 10.1016/j.bej.2018.10.023] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
129
|
Almaliti J, Miller B, Pietraszkiewicz H, Glukhov E, Naman CB, Kline T, Hanson J, Li X, Zhou S, Valeriote FA, Gerwick WH. Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents. Eur J Med Chem 2019; 161:416-432. [PMID: 30384045 PMCID: PMC6248884 DOI: 10.1016/j.ejmech.2018.10.024] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Revised: 09/25/2018] [Accepted: 10/09/2018] [Indexed: 02/06/2023]
Abstract
Antibody-drug conjugates (ADCs) represent a new dimension of anticancer chemotherapeutics, with warheads to date generally involving either antitubulin or DNA-directed agents to achieve low-to sub-nanomolar potency. However, other potent cytotoxins working by different pharmacological mechanisms are under investigation, such as α,β-epoxyketone based proteasome inhibitors. These proteasome active agents are an emerging class of anticancer drug that possesses ultra-potent cytotoxicity to some cancer cell lines. The carmaphycins are representatives of this latter class that we isolated and characterized from a marine cyanobacterium, and these as well as several synthetic analogues exhibit this level of potency. In the current work, we investigated the use of these highly potent cytotoxic compounds as warheads in the design of novel ADCs. We designed and synthesized a library of carmaphycin B analogues that contain amine handles, enabling their attachment to an antibody linker. The basicity of these incorporated amine handles was shown to strongly affect their cytotoxic properties. Linear amines resulted in the greatest reduction in cytotoxicity whereas less basic aromatic amines retained potent activity as demonstrated by a 4-sulfonylaniline derivative. These investigations resulted in identifying the P2 residue in the carmaphycins as the most suitable site for linker attachment point, and hence, we synthesized a highly potent analogue of carmaphycin B that contained a 4-sulfonylaniline handle as an attachment point for the linker antibody.
Collapse
Affiliation(s)
- Jehad Almaliti
- Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, 92093, United States; Department Pharmaceutical Sciences, College of Pharmacy, The University of Jordan, Amman, 11942, Jordan
| | - Bailey Miller
- Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, 92093, United States
| | - Halina Pietraszkiewicz
- Department of Internal Medicine, Division of Hematology and Oncology, Henry Ford Hospital, Detroit, MI, 48202, USA
| | - Evgenia Glukhov
- Department Pharmaceutical Sciences, College of Pharmacy, The University of Jordan, Amman, 11942, Jordan
| | - C Benjamin Naman
- Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, 92093, United States; College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang, 315211, China
| | - Toni Kline
- Sutro Biopharma, South San Francisco, CA, 94080, United States
| | - Jeffrey Hanson
- Sutro Biopharma, South San Francisco, CA, 94080, United States
| | - Xiaofan Li
- Sutro Biopharma, South San Francisco, CA, 94080, United States
| | - Sihong Zhou
- Sutro Biopharma, South San Francisco, CA, 94080, United States
| | - Frederick A Valeriote
- Department of Internal Medicine, Division of Hematology and Oncology, Henry Ford Hospital, Detroit, MI, 48202, USA
| | - William H Gerwick
- Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, 92093, United States; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, 92093, United States.
| |
Collapse
|
130
|
Tippmann EM, Culpepper S, Bunnel W, Appel N. New perspectives on aryl azide noncanonical amino acid use in yeast. Photochem Photobiol Sci 2019; 18:253-258. [DOI: 10.1039/c8pp00243f] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
A photochemically chemically active noncanonical amino acidpara-azido-l-phenylalanine widely used in biology was found to be metabolized bySaccharomyces cerevisiae.
Collapse
|
131
|
Abstract
Conventional antibody-drug conjugates (ADCs) randomly assemble small-molecule drugs onto Lys or Cys residues of a tumor-targeting antibody, featured with heterogeneity in payload numbers and conjugation positions. Glycosite-specific ADCs (gsADCs) link payload drugs onto IgG Fc N-glycans with high homogeneity that facilitates structural optimization and quality control for ADC drug development. In this protocol, we report two strategies for preparation of homogeneous ADCs via chemoenzymatic glycoengineering. First, an azido-tagged unnatural N-glycan substrate is transferred onto Fc glycosites of a therapeutic antibody through Endo-S-catalyzed glycoremodeling, followed by click reaction with an alkyne-tagged payload drug to give a well-defined gsADC. In an alternative way, glycoengineering of antibody with a natural sialylated N-glycan and successive selective oxidation of sialic acid moieties using sodium periodate provided an aldehyde handle on the glycans for conjugation with an aminooxy-assembled payload. These two strategies both enable gsADCs with high homogeneity in their conjugation sites, payload numbers, and glycoforms, which are characterized of a single mass under mass-spectral detection.
Collapse
Affiliation(s)
- Feng Tang
- CAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Pudong, Shanghai, China
- University of Chinese Academy of Sciences, Beijing, People's Republic of China
| | - Wei Shi
- CAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Pudong, Shanghai, China
- University of Chinese Academy of Sciences, Beijing, People's Republic of China
| | - Wei Huang
- CAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Pudong, Shanghai, China.
- University of Chinese Academy of Sciences, Beijing, People's Republic of China.
| |
Collapse
|
132
|
Xie H, Adjei AA. Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. J Thorac Oncol 2018; 14:358-376. [PMID: 30599202 DOI: 10.1016/j.jtho.2018.11.034] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 11/25/2018] [Accepted: 11/29/2018] [Indexed: 10/27/2022]
Abstract
Antibody-drug conjugates (ADCs) are a novel class of therapeutic agents incorporating both target-specific monoclonal antibodies and cytotoxic small molecules via a chemical linker. They were first introduced into the clinic for the treatment of advanced hematologic malignancies. The only approved ADC for solid tumors targets erb-b2 receptor tyrosine kinase (HER2), a validated antigen in breast cancer. Many ADCs are under active investigation for various types of solid tumors. In this article, we review the literature from several perspectives including the design, pharmacology, and mechanism-based toxicities of antibody-drug conjugates. We then discuss ADCs currently in clinical development for thoracic malignancies.
Collapse
Affiliation(s)
- Hao Xie
- Mayo Clinic, Rochester, Minnesota
| | | |
Collapse
|
133
|
Abrahams CL, Li X, Embry M, Yu A, Krimm S, Krueger S, Greenland NY, Wen KW, Jones C, DeAlmeida V, Solis WA, Matheny S, Kline T, Yam AY, Stafford R, Wiita AP, Hallam T, Lupher M, Molina A. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. Oncotarget 2018; 9:37700-37714. [PMID: 30701025 PMCID: PMC6340874 DOI: 10.18632/oncotarget.26491] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2018] [Accepted: 12/04/2018] [Indexed: 01/22/2023] Open
Abstract
STRO-001 is a site-specific, predominantly single-species, fully human, aglycosylated anti-CD74 antibody-drug conjugate incorporating a non-cleavable linker-maytansinoid warhead with a drug-antibody ratio of 2 which was produced by a novel cell-free antibody synthesis platform. We examined the potential pharmacodynamics and anti-tumor effects of STRO-001 in multiple myeloma (MM). CD74 expression was assessed in MM cell lines and primary bone marrow (BM) MM biopsies. CD74 mRNA was detectable in CD138+ enriched plasma cells from 100% (892/892) of patients with newly diagnosed MM. Immunohistochemistry confirmed CD74 expression in 35/36 BM biopsies from patients with newly diagnosed and relapsed/refractory MM. Cytotoxicity assays demonstrated nanomolar STRO-001 potency in 4/6 MM cell lines. In ARP-1 and MM.1S tumor-bearing mice, repeat STRO-001 dosing provided significant antitumor activity with eradication of malignant hCD138+ BM plasma cells and prolonged survival. In a luciferase-expressing MM.1S xenograft model, dose-dependent STRO-001 efficacy was confirmed using bioluminescent imaging and BM tumor burden quantification. Consistent with the intended pharmacodynamic effect, STRO-001 induced dose-responsive, reversible B-cell and monocyte depletion in cynomolgus monkeys, up to a maximum tolerated 10 mg/kg, with no evidence of off-target toxicity. Collectively, these data suggest that STRO-001 is a promising therapeutic agent for the treatment of MM.
Collapse
Affiliation(s)
| | - Xiaofan Li
- Sutro Biopharma, Inc., South San Francisco, California, USA
| | | | - Abigail Yu
- Sutro Biopharma, Inc., South San Francisco, California, USA
| | | | | | - Nancy Y Greenland
- Department of Pathology and Laboratory Medicine, University of California, San Francisco, CA, USA
| | - Kwun Wah Wen
- Department of Pathology and Laboratory Medicine, University of California, San Francisco, CA, USA
| | - Chris Jones
- Department of Pathology and Laboratory Medicine, University of California, San Francisco, CA, USA
| | | | - Willy A Solis
- Sutro Biopharma, Inc., South San Francisco, California, USA
| | | | - Toni Kline
- Sutro Biopharma, Inc., South San Francisco, California, USA
| | - Alice Y Yam
- Sutro Biopharma, Inc., South San Francisco, California, USA
| | - Ryan Stafford
- Sutro Biopharma, Inc., South San Francisco, California, USA
| | - Arun P Wiita
- Department of Pathology and Laboratory Medicine, University of California, San Francisco, CA, USA
| | - Trevor Hallam
- Sutro Biopharma, Inc., South San Francisco, California, USA
| | - Mark Lupher
- Sutro Biopharma, Inc., South San Francisco, California, USA
| | - Arturo Molina
- Sutro Biopharma, Inc., South San Francisco, California, USA
| |
Collapse
|
134
|
van Berkel SS, van Delft FL. Enzymatic strategies for (near) clinical development of antibody-drug conjugates. DRUG DISCOVERY TODAY. TECHNOLOGIES 2018; 30:3-10. [PMID: 30553518 DOI: 10.1016/j.ddtec.2018.09.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 09/21/2018] [Accepted: 09/22/2018] [Indexed: 05/20/2023]
Abstract
Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer. However, despite more than 20 years of clinical development, only four ADC have reached market approval, while at least 50 clinical programs were terminated early. The high attrition rate of ADCs may, at least in part, be attributed to heterogeneity and instability of conventional technologies. At present, various (chemo)enzymatic approaches for site-specific and stable conjugation of toxic payloads are making their way to the clinic, thereby potentially providing ADCs with increased therapeutic window.
Collapse
Affiliation(s)
| | - Floris L van Delft
- Synaffix BV, Kloosterstraat 9, 5349 AB, Oss, The Netherlands; Wageningen University and Research, Laboratory of Organic Chemistry, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
| |
Collapse
|
135
|
Bundy BC, Hunt JP, Jewett MC, Swartz JR, Wood DW, Frey DD, Rao G. Cell-free biomanufacturing. Curr Opin Chem Eng 2018. [DOI: 10.1016/j.coche.2018.10.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
136
|
ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates. Antibodies (Basel) 2018; 7:antib7040041. [PMID: 31544891 PMCID: PMC6698957 DOI: 10.3390/antib7040041] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 11/21/2018] [Accepted: 11/26/2018] [Indexed: 12/19/2022] Open
Abstract
Antibody-drug conjugates (ADCs) are a unique class of biotherapeutics of inherent heterogeneity and correspondingly complex absorption, distribution, metabolism, and excretion (ADME) properties. Herein, we consider the contribution of various components of ADCs such as various classes of warheads, linkers, and conjugation strategies on ADME of ADCs. Understanding the metabolism and disposition of ADCs and interpreting exposure-efficacy and exposure-safety relationships of ADCs in the context of their various catabolites is critical for design and subsequent development of a clinically successful ADCs. Sophisticated bioanalytical assays are required for the assessments of intact ADC, total antibody, released warhead and relevant metabolites. Both ligand-binding assays (LBA) and hybrid LBA-liquid chromatography coupled with tandem mass spectrometry (LBA-LC-MS/MS) methods have been employed to assess pharmacokinetics (PK) of ADCs. Future advances in bioanalytical techniques will need to address the rising complexity of this biotherapeutic modality as more innovative conjugation strategies, antibody scaffolds and novel classes of warheads are employed for the next generation of ADCs. This review reflects our considerations on ADME of ADCs and provides a perspective on the current bioanalytical strategies for pharmacokinetic assessments of ADCs.
Collapse
|
137
|
Frutos S, Hernández JL, Otero A, Calvis C, Adan J, Mitjans F, Vila-Perelló M. Site-Specific Antibody Drug Conjugates Using Streamlined Expressed Protein Ligation. Bioconjug Chem 2018; 29:3503-3508. [PMID: 30346741 DOI: 10.1021/acs.bioconjchem.8b00630] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Antibody-Drug Conjugates (ADCs) have been shown to produce clinical benefit in cancer patient thanks to their ability to target highly cytotoxic small molecules to tumor cells. However, the development of these complex molecules faces significant challenges due to the need to combine a large biologic drug with a small molecule drug to generate the desired bioconjugate. We describe here the use of a protein ligation methodology, based on the native chemical ligation reaction to generate site-specific Antibody-Drug Conjugates, which does not require the incorporation of unnatural modifications into the antibody. Fully native antibodies, with only the desired cytotoxic molecules attached, can be generated, thus minimizing the risk that additional modifications required for the site-specific conjugation pose a risk to the antibody activity. We demonstrate that our approach can be used to generate site-specifically modified ADCs, with potent in vitro and in vivo antitumor activity in a breast cancer tumor model.
Collapse
Affiliation(s)
- Silvia Frutos
- ProteoDesign , C/Baldiri Reixach 10 , Barcelona 08028 , Spain
| | - Jose Luis Hernández
- LEITAT Technological Center , Biomed Division , C/Baldiri Reixach 15-21 , Barcelona 08028 , Spain
| | - Anabel Otero
- ProteoDesign , C/Baldiri Reixach 10 , Barcelona 08028 , Spain
| | - Carme Calvis
- LEITAT Technological Center , Biomed Division , C/Baldiri Reixach 15-21 , Barcelona 08028 , Spain
| | - Jaume Adan
- LEITAT Technological Center , Biomed Division , C/Baldiri Reixach 15-21 , Barcelona 08028 , Spain
| | - Francesc Mitjans
- LEITAT Technological Center , Biomed Division , C/Baldiri Reixach 15-21 , Barcelona 08028 , Spain
| | | |
Collapse
|
138
|
Zhao S, Molina A, Yu A, Hanson J, Cheung H, Li X, Natkunam Y. High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti-CD74-drug conjugate. JOURNAL OF PATHOLOGY CLINICAL RESEARCH 2018; 5:12-24. [PMID: 30191677 PMCID: PMC6317062 DOI: 10.1002/cjp2.114] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Revised: 08/17/2018] [Accepted: 09/04/2018] [Indexed: 12/14/2022]
Abstract
CD74 is a type II transmembrane glycoprotein that functions as an MHC class II chaperone and displays diverse roles in immune responses. Recently, anti‐CD74 immunotherapy has shown promise as an effective treatment strategy for lymphoid neoplasms in preclinical models. Using a human anti‐CD74 antibody (SP7219), we defined the expression of CD74 protein in both normal and over 790 neoplastic hematolymphoid tissue samples. We found that CD74 is expressed broadly in normal B‐cell compartments including primary and secondary lymphoid follicles and in the thymic medulla. The vast majority of lymphomas expressed CD74, including Hodgkin lymphomas (98%), B‐cell lymphomas (96%), extranodal NK/T‐cell lymphomas (88%), mature T‐cell lymphomas (80%), and plasma cell myeloma (75%). Our findings confirm and expand previous observations regarding the expression of CD74 and suggest that CD74 expression on tumor cells may be directly targeted for immunomodulatory therapy for lymphoid and plasma cell malignancies.
Collapse
Affiliation(s)
- Shuchun Zhao
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | | | | | | | | | | | - Yasodha Natkunam
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
139
|
Kang M, Lu Y, Chen S, Tian F. Harnessing the power of an expanded genetic code toward next-generation biopharmaceuticals. Curr Opin Chem Biol 2018; 46:123-129. [DOI: 10.1016/j.cbpa.2018.07.018] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 04/30/2018] [Accepted: 07/13/2018] [Indexed: 10/28/2022]
|
140
|
Akgun B, Hall DG. Boronic Acids as Bioorthogonal Probes for Site‐Selective Labeling of Proteins. Angew Chem Int Ed Engl 2018; 57:13028-13044. [DOI: 10.1002/anie.201712611] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Revised: 04/23/2018] [Indexed: 12/11/2022]
Affiliation(s)
- Burcin Akgun
- Department of Chemistry—CCIS 4–010University of Alberta Edmonton Alberta T6G 2G2 Canada
| | - Dennis G. Hall
- Department of Chemistry—CCIS 4–010University of Alberta Edmonton Alberta T6G 2G2 Canada
| |
Collapse
|
141
|
Oller-Salvia B. Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction. J Vis Exp 2018. [PMID: 30272643 PMCID: PMC6235180 DOI: 10.3791/58066] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Antibody-drug conjugates (ADCs) used nowadays in clinical practice are mixtures of antibody molecules linked to a varying number of toxins at different positions. Preclinical studies have shown that the therapeutic index of these traditional ADCs can be improved by the site-specific linkage of toxins. However, current approaches to produce homogeneous ADCs have several limitations, such as low protein expression and slow reaction kinetics. In this protocol we describe how to set up an expression system to incorporate a cyclopropene derivative of lysine (CypK) into antibodies using genetic code expansion. This minimal bioorthogonal handle allows rapid conjugation of tetrazine derivatives through an inverse-demand Diels-Alder cycloaddition. The expression system here reported enables the facile production and purification of trastuzumab bearing CypK in each of the heavy chains. We explain how to link the antibody to the toxin monomethyl auristatin E and characterize the immunoconjugate by hydrophobic interaction chromatography and mass spectrometry. Finally, we describe assays to assess the stability in human serum of the dihydropyridazine linkage resulting from the conjugation and to test the selective cytotoxicity of the ADC for breast cancer cells with high levels of HER2 receptor.
Collapse
|
142
|
Akgun B, Hall DG. Boronsäuren als bioorthogonale Sonden für zentrenselektives Protein‐Labeling. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201712611] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Burcin Akgun
- Department of Chemistry – CCIS 4-010University of Alberta Edmonton Alberta T6G 2G2 Kanada
| | - Dennis G. Hall
- Department of Chemistry – CCIS 4-010University of Alberta Edmonton Alberta T6G 2G2 Kanada
| |
Collapse
|
143
|
Beaumont M, Tomazela D, Hodges D, Ermakov G, Hsieh E, Figueroa I, So OY, Song Y, Ma H, Antonenko S, Mengesha W, Zhang YW, Zhang S, Hseih S, Ayanoglu G, Du X, Rimmer E, Judo M, Vives F, Yearley JH, Moon C, Manibusan A, Knudsen N, Beck A, Bresson D, Gately D, Neupane D, Escandón E. Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection. AAPS OPEN 2018. [DOI: 10.1186/s41120-018-0026-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
144
|
Andris S, Wendeler M, Wang X, Hubbuch J. Multi-step high-throughput conjugation platform for the development of antibody-drug conjugates. J Biotechnol 2018; 278:48-55. [DOI: 10.1016/j.jbiotec.2018.05.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Revised: 04/27/2018] [Accepted: 05/03/2018] [Indexed: 12/01/2022]
|
145
|
d'Aquino AE, Kim DS, Jewett MC. Engineered Ribosomes for Basic Science and Synthetic Biology. Annu Rev Chem Biomol Eng 2018; 9:311-340. [DOI: 10.1146/annurev-chembioeng-060817-084129] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The ribosome is the cell's factory for protein synthesis. With protein synthesis rates of up to 20 amino acids per second and at an accuracy of 99.99%, the extraordinary catalytic capacity of the bacterial translation machinery has attracted extensive efforts to engineer, reconstruct, and repurpose it for biochemical studies and novel functions. Despite these efforts, the potential for harnessing the translation apparatus to manufacture bio-based products beyond natural limits remains underexploited, and fundamental constraints on the chemistry that the ribosome's RNA-based active site can carry out are unknown. This review aims to cover the past and present advances in ribosome design and engineering to understand the fundamental biology of the ribosome to facilitate the construction of synthetic manufacturing machines. The prospects for the development of engineered, or designer, ribosomes for novel polymer synthesis are reviewed, future challenges are considered, and promising advances in a variety of applications are discussed.
Collapse
Affiliation(s)
- Anne E. d'Aquino
- Interdisciplinary Biological Sciences Graduate Program, Northwestern University, Evanston, Illinois 60208, USA
- Center for Synthetic Biology, Northwestern University, Evanston, Illinois 60208, USA
| | - Do Soon Kim
- Center for Synthetic Biology, Northwestern University, Evanston, Illinois 60208, USA
- Department of Chemical and Biological Engineering, Northwestern University, Evanston, Illinois 60208, USA
| | - Michael C. Jewett
- Interdisciplinary Biological Sciences Graduate Program, Northwestern University, Evanston, Illinois 60208, USA
- Center for Synthetic Biology, Northwestern University, Evanston, Illinois 60208, USA
- Department of Chemical and Biological Engineering, Northwestern University, Evanston, Illinois 60208, USA
| |
Collapse
|
146
|
Shao S, Tsai MH, Lu J, Yu T, Jin J, Xiao D, Jiang H, Han M, Wang M, Wang J. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. Bioorg Med Chem Lett 2018; 28:1363-1370. [DOI: 10.1016/j.bmcl.2018.03.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Revised: 02/28/2018] [Accepted: 03/02/2018] [Indexed: 01/19/2023]
|
147
|
Supekova L, Zambaldo C, Choi S, Lim R, Luo X, Kazane SA, Young TS, Schultz PG. The genetic incorporation of p-azidomethyl-l-phenylalanine into proteins in yeast. Bioorg Med Chem Lett 2018; 28:1570-1573. [DOI: 10.1016/j.bmcl.2018.03.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 03/19/2018] [Accepted: 03/21/2018] [Indexed: 11/24/2022]
|
148
|
Zhang C, Dai P, Vinogradov AA, Gates ZP, Pentelute BL. Site-Selective Cysteine-Cyclooctyne Conjugation. Angew Chem Int Ed Engl 2018; 57:6459-6463. [PMID: 29575377 DOI: 10.1002/anie.201800860] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 03/07/2018] [Indexed: 11/06/2022]
Abstract
We report a site-selective cysteine-cyclooctyne conjugation reaction between a seven-residue peptide tag (DBCO-tag, Leu-Cys-Tyr-Pro-Trp-Val-Tyr) at the N or C terminus of a peptide or protein and various aza-dibenzocyclooctyne (DBCO) reagents. Compared to a cysteine peptide control, the DBCO-tag increases the rate of the thiol-yne reaction 220-fold, thereby enabling selective conjugation of DBCO-tag to DBCO-linked fluorescent probes, affinity tags, and cytotoxic drug molecules. Fusion of DBCO-tag with the protein of interest enables regioselective cysteine modification on proteins that contain multiple endogenous cysteines; these examples include green fluorescent protein and the antibody trastuzumab. This study demonstrates that short peptide tags can aid in accelerating bond-forming reactions that are often slow to non-existent in water.
Collapse
Affiliation(s)
- Chi Zhang
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Peng Dai
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Alexander A Vinogradov
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Zachary P Gates
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Bradley L Pentelute
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| |
Collapse
|
149
|
Zhang C, Dai P, Vinogradov AA, Gates ZP, Pentelute BL. Site‐Selective Cysteine–Cyclooctyne Conjugation. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201800860] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Chi Zhang
- Department of Chemistry Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - Peng Dai
- Department of Chemistry Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - Alexander A. Vinogradov
- Department of Chemistry Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - Zachary P. Gates
- Department of Chemistry Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - Bradley L. Pentelute
- Department of Chemistry Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| |
Collapse
|
150
|
Spangler B, Kline T, Hanson J, Li X, Zhou S, Wells JA, Sato AK, Renslo AR. Toward a Ferrous Iron-Cleavable Linker for Antibody–Drug Conjugates. Mol Pharm 2018; 15:2054-2059. [DOI: 10.1021/acs.molpharmaceut.8b00242] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Benjamin Spangler
- Graduate Program in Chemistry & Chemical Biology, University of California, San Francisco, California 94143, United States
| | - Toni Kline
- Sutro Biopharma, Inc., South San Francisco, California 94080, United States
| | - Jeffrey Hanson
- Sutro Biopharma, Inc., South San Francisco, California 94080, United States
| | - Xiaofan Li
- Sutro Biopharma, Inc., South San Francisco, California 94080, United States
| | - Sihong Zhou
- Sutro Biopharma, Inc., South San Francisco, California 94080, United States
| | | | - Aaron K. Sato
- Sutro Biopharma, Inc., South San Francisco, California 94080, United States
| | | |
Collapse
|